Johnson & Johnson (JNJ) Stock Rating Reaffirmed by Morgan Stanley
Johnson & Johnson (NYSE:JNJ)‘s stock had its “equal weight” rating restated by equities researchers at Morgan Stanley in a research note issued on Friday. They presently have a $135.00 price objective on the stock, up from their prior price objective of $130.00. Morgan Stanley’s price target indicates a potential upside of 6.32% from the company’s previous close.
JNJ has been the subject of several other reports. Vetr cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $124.53 price objective for the company. in a research note on Thursday, February 23rd. Goldman Sachs Group Inc decreased their price objective on shares of Johnson & Johnson from $120.00 to $115.00 and set a “neutral” rating for the company in a research note on Wednesday, January 25th. Wells Fargo & Co cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and lifted their price objective for the company from $112.28 to $112.80 in a research note on Thursday, January 26th. JPMorgan Chase & Co. upgraded shares of Johnson & Johnson from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $123.64 to $140.00 in a research note on Monday, May 15th. Finally, Stifel Nicolaus restated a “hold” rating and set a $128.00 price objective (up from $124.00) on shares of Johnson & Johnson in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $128.51.
Shares of Johnson & Johnson (NYSE:JNJ) opened at 127.00 on Friday. The firm’s 50-day moving average is $124.19 and its 200-day moving average is $119.23. The stock has a market capitalization of $342.12 billion, a PE ratio of 21.35 and a beta of 0.74. Johnson & Johnson has a one year low of $109.32 and a one year high of $129.00.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 18th. The company reported $1.83 EPS for the quarter, beating the consensus estimate of $1.77 by $0.06. Johnson & Johnson had a net margin of 22.78% and a return on equity of 25.61%. The business had revenue of $17.77 billion during the quarter, compared to analysts’ expectations of $18.02 billion. During the same period in the previous year, the business posted $1.68 EPS. The business’s quarterly revenue was up 1.6% compared to the same quarter last year. On average, analysts expect that Johnson & Johnson will post $7.10 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 13th. Investors of record on Tuesday, May 30th will be issued a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.65%. The ex-dividend date is Thursday, May 25th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.80. Johnson & Johnson’s payout ratio is presently 54.42%.
COPYRIGHT VIOLATION NOTICE: “Johnson & Johnson (JNJ) Stock Rating Reaffirmed by Morgan Stanley” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/05/20/johnson-johnson-jnj-stock-rating-reaffirmed-by-morgan-stanley.html.
Large investors have recently modified their holdings of the company. Moreno Evelyn V raised its stake in shares of Johnson & Johnson by 3.9% in the third quarter. Moreno Evelyn V now owns 54,421 shares of the company’s stock valued at $4,984,000 after buying an additional 2,053 shares during the last quarter. Watch Point Trust Co raised its stake in Johnson & Johnson by 1.7% in the third quarter. Watch Point Trust Co now owns 17,685 shares of the company’s stock worth $2,089,000 after buying an additional 300 shares during the last quarter. Rathbone Brothers plc raised its stake in Johnson & Johnson by 2.9% in the third quarter. Rathbone Brothers plc now owns 309,243 shares of the company’s stock worth $36,531,000 after buying an additional 8,619 shares during the last quarter. Cottage Street Advisors LLC raised its stake in Johnson & Johnson by 10.7% in the third quarter. Cottage Street Advisors LLC now owns 12,643 shares of the company’s stock worth $1,494,000 after buying an additional 1,223 shares during the last quarter. Finally, Saddle Road Partners LLC raised its stake in Johnson & Johnson by 5.7% in the third quarter. Saddle Road Partners LLC now owns 40,523 shares of the company’s stock worth $4,787,000 after buying an additional 2,190 shares during the last quarter. 65.30% of the stock is owned by institutional investors.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.